Last reviewed · How we verify
NCT05573815
Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images
NA trial testing BT-M01 in Brain Metastases in 558 participants. Status unknown.
30 November 2022
Quick facts
| Lead sponsor | Heuron Inc. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 558 |
| Start date | 16 September 2022 |
| Primary completion | 30 November 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- BT-M01
Conditions studied
- Brain Metastases — all drugs for Brain Metastases →
Sponsor
Heuron Inc.
Who can join
19 and older, any sex, with Brain Metastases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
BT-M01 is a software that has been pre-learned based on a brain metastasis detection model using brain MR images, and clinical decision support system for brain metastasis by automatically analyzing brain MR images by assisting the medical team. The specific aims of this study are to evaluate efficacy of BT-M01 for brain metastasis compared to the sensitivity and false positive rates of radiologists group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05573815
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Brain Metastases
Currently open trials in the same condition.
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07481786 — Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases · Phase 3 · recruiting
- NCT07227610 — Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT) · Phase 2 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
- NCT07053033 — Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR Be · Phase 2 · recruiting
Other Heuron Inc. trials
Trials by the same sponsor.
- NCT05513794 — Prospective Study for Neuromelanin Image Analysis · NA · completed
- NCT05572619 — Evaluation of Clinical Decision Support System for Large Vessel Occlusion Using Brain CT Images · completed
- NCT04983927 — Evaluation of Clinical Decision Support System for Scoring of ASPECT Score Using Brain CT Images · completed
- NCT04983953 — Evaluation of Clinical Decision Support System for Intracranial Hemorrhage Using Brain CT Images · completed
- NCT04334902 — Evaluation of Clinical Decision Support System-mPDia for Neurodegenerative Parkinsonism Using MRI Images · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05573815 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Heuron Inc.
- Last refreshed: 10 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05573815.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing